Atlas of Rheumatoid Arthritis

Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009-2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National Institute for Health Research(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award forClinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULARPrize for outstanding contribution to rheumatology research; and the Carol Nachman Prizefor outstanding rheumatology research. Professor Emery's research interests center around theimmunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connectivetissue diseases. He has a special interest in the factors leading to persistent inflammationand has published over 950 peer-reviewed articles in this area.is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the LeedsMusculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, UnitedKingdom. Professor Emery was the President of the European League Against Rheumatism(EULAR) from 2009-2011 and has served on the editorial boards major rheumatology journalsincluding Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinicaland Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President ofInternational Extremity MRI Society (ISEMIR) and is a National Institute for Health Research(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award forClinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULARPrize for outstanding contribution to rheumatology research; and the Carol Nachman Prizefor outstanding rheumatology research. Professor Emery's research interests center around theimmunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connectivetissue diseases. He has a special interest in the factors leading to persistent inflammationand has published over 950 peer-reviewed articles in this area.

Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography.

The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA.

Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.

A high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of dozens relevant images, with extended descriptive captions and a comprehensive bibliography

1. Classification of rheumatoid arthritis

2. Pre-rheumatoid arthritis

What is pre-rheumatoid arthritis?

Risk factors for rheumatoid arthritis

Systemic autoimmunity associated with rheumatoid arthritis

Symptoms without clinical arthritis

Unclassified arthritis

3. Early rheumatoid arthritis

Introduction

Pathology in early rheumatoid arthritis

Diagnosis of early rheumatoid arthritis

Classification of rheumatoid arthritis

Management of early rheumatoid arthritis

Recommendations for the management of early rheumatoid arthritis

4. Established rheumatoid arthritis

Introduction

Stages of established rheumatoid arthritis

Common clinical presentations

Introduction

Stages of established rheumatoid arthritis

Common clinical presentations

5. Remission and rheumatoid arthritis

Introduction

Defining remission

Imaging remission

Immune-mediated remission

Drug-free remission

Optimal dose reduction regimes for patients in remission

Part TWO Imaging of Rheumatoid Arthritis

6. Magnetic resonance imaging in rheumatoid arthritis

Introduction

Technical aspects

Visualizing rheumatoid arthritis

Diagnosing rheumatoid arthritis

Monitoring disease activity and structural damage

7. Ultrasound imaging in rheumatoid arthritis

7. Ultrasound imaging in rheumatoid arthritis

Introduction

Ultrasound and rheumatoid arthritis

Cartilage damage

Management of rheumatoid arthritis with ultrasound: diagnosis, therapeutic follow-up, remission, and flare

Conclusion

8. Dual energy X-ray absorptiometry in rheumatoid arthritis

Introduction

Bone remodeling in rheumatoid arthritis

Bone damage imaging in rheumatoid arthritis

Treatment of bone loss in rheumatoid arthritis

Part three Treatment of rheumatoid arthritis

9. Methotrexate

Introduction

Historical perspective

Mechanism of action and pharmacokinetics

Dosing

Benefits

Monitoring

10. Immunotherapy

Introduction

Nonbiologic disease-modifying antirheumatic drugs

Biologic disease-modifying antirheumatic drugs

Cost-effectiveness of immunotherapy in early rheumatoid arthritis

Recommendations for the use of disease-modifying antirheumatic drug therapies

Safety of immunotherapy

Prospective new targets for immunotherapy

11. Rituximab

B-cell development and differentiation

Efficacy of rituximab in rheumatoid arthritis

12. Novel therapies in rheumatoid arthritis: small molecules

Introduction

Inhibiting intracellular signaling pathways

Conclusion